MO-VERNE-GLOBAL
15.11.2021 14:02:11 CET | Business Wire | Press release
Verne Global , provider of sustainable data center solutions for high intensity computing, recently acquired by Digital 9 Infrastructure plc (D9), today announced that it is expanding its 40-acre data center campus by a further 10MW of constructed power capacity. The expansion is backed by D9, the investment trust that focuses on sustainable digital infrastructure assets, which will fund the $50m development of new enterprise-class data center space.
Ideally located with access to abundant, low-cost renewable energy and a highly reliable national electrical grid, the Icelandic data center company continues to attract a range of enterprise customers as demand for high intensity compute sees sustained growth across industries. As more companies look to decarbonize their digital infrastructure by powering intensive applications such as artificial intelligence, mathematical modelling and predictive analytics with cleaner, greener energy, Verne Global is expanding now to meet contracted demand. The data center company’s best-in-class onsite technical and operations team will continue to use its specialized expertise to work around the clock to support and optimize the high density environments and workloads it houses.
“We’re seeing sector after sector looking to move into high performance analytics environments and it’s exciting to scale our campus again alongside new and existing customers to meet that need,” said Dominic Ward, CEO at Verne Global. “It’s great to also take this first step into the future as part of the D9 Infrastructure platform, and we are all eagerly looking forward to what comes next.”
“We are proud to support Verne Global and play a part in bringing its vision for the future into reality,” said Thor Johnsen, Head of Digital Infrastructure at Triple Point, D9’s investment manager. “Powered by Iceland’s abundant green power, Verne Global’s expanded data center will be even better placed to provide resilient digital infrastructure that offers a true reduction in carbon emissions for its customers alongside long-term economic and sustainable stability.”
As part of this expansion, Verne Global is partnering with Integra Mission Critical , the modular data center solutions provider, to optimize its delivery of sustainable high intensity compute at scale while fitting out the new data center space. Utilizing Integra’s solution-driven engineering expertise to implement modular data center infrastructure will allow Verne Global to increase sustainability measures in line with its core mission, while promoting scalability and safety, and decreasing cost.
“Verne Global’s facility has been built from the ground up for highly specialist data center services that are sustainable, scalable and bespoke,” said John Kolar, Principal at Integra Mission Critical. “These mutual principles make our companies a natural fit and we’re so excited to be teaming up and putting our decades of experience in solution-driven engineering to good use to provide a quality turnkey infrastructure solution for the new space.”
SC21 delegates can visit Verne Global at the Data Centers by Iceland stand (#1819) at SC21 in St Louis, MO, 15-19 November, 2021.
About Verne Global
Verne Global delivers data center solutions for high intensity computing, engineered for optimal high performance compute and built upon 100% renewable energy. Our clean grid and stable climate cuts costs and energy usage, and our expert team provides on-site, around-the-clock support to maximize performance and flexibility for customer workloads.
Founded in 2012, our Icelandic data center campus powers some of the world’s most innovative and demanding industries, including financial services, earth sciences, life sciences, engineering, scientific research and AI.
About Integra Mission Critical
Integra Mission Critical delivers modular mechanical, electrical and plumbing (MEP) solutions for the mission critical sector. With in-house manufacturing facilities throughout the United States, Europe, and Asia, Integra Mission Critical has a global reach with a local focus. Our solutions-driven engineering enables us to meet each customer’s specific needs across the globe, whether that be specialized cooling for a specific climate, or sustainable solutions for backup power generation.
Integra Mission Critical leverages innovative designs and an integrated approach and combines them with our relentless passion to mitigate risk, compress the schedule, reduce costs, and close the gap between capex and revenue generation.
Founded in 2014, with a focus on cooling solutions, Integra Mission Critical has since expanded into electrical solutions (2017), ranging from electrical skids to modular electrical rooms, to complete modular data centers. Our North America headquarters are in Dallas, Texas with our European headquarters in London, England.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005074/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom